Latest News

Launch of Mucodis® Rectal Gel
Mucodis® Rectal Gel

Launch of Mucodis® Rectal Gel

Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, is pleased to announce that Colonis, part of the Group's Niche Pharmaceuticals division, has launched its Mucodis® Rectal Gel for the prevention and treatment of rectal mucositis, a common side effect of chemotherapy and radiotherapy in cancer patients.

Mucositis is a condition characterised by pain and inflammation of the body's mucous membranes which line the digestive system from the mouth to the anus1. Of the circa 352,000 newly diagnosed cancer patients every year in the UK, 34% or approximately 118,000 patients have cancers situated in the lower abdominal or pelvic areas2. Estimates indicate that 90,000 people are living with chronic changes in lower GI function following radiotherapy or surgery from pelvic cancers3. These patients may be affected by rectal mucositis (Proctitis) which includes painful ulcers and bleeding in the patient's rectum and anus2.

Mucodis® Rectal Gel is the penultimate product to be launched in the initial Mucodis® range of 5 products which provides the NHS with prescribable products to address a number of the side effects associated with cancer treatments including mucositis, radiation-induced dermatitis, vulvovaginitis and proctitis. Colonis has been granted an exclusive distribution licence for these products for 5 years, with an option to extend beyond this initial period.

Andrew Scaife, Chief Executive of Quantum Pharma Plc, commented: "We are delighted to be able to provide this treatment to help aid proctitis, a painful and often incapacitating symptom associated with cancer treatment. We are excited by the potential that the Mucodis® range offers the NHS and patients as there is a clear unmet need for this type of relief and we are confident that our products will have a significant effect on improving patients' quality of life."

Footnotes

1. NHS Conditions, Mucositis (accessed June 2016)
2. Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence#heading-One (accessed June 2016)
3. Macmillan Cancer Support. Throwing light on the consequences of cancer and its treatment. Available from: http://www.macmillan.org.uk/Documents/AboutUs/Researchandevaluationreports/Throwingthelight report.pdf (Accessed April 2016)

Posted by: Quantum Webmaster on 26th July 2016